Can pharmacogenetics help rescue drugs withdrawn from the market? (Q36596713)

15 August 2017

1 reference

title

Can pharmacogenetics help rescue drugs withdrawn from the market? (English)

1 reference

15 August 2017

Rashmi R Shah

1

1 reference

15 August 2017

language of work or name

1 reference

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

889-908

1 reference

Pharmacogenomics: the inherited basis for interindividual differences in drug response

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics-based new therapeutic concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics in drug regulation: promise, potential and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Measuring the value of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Clinical pharmacogenetics of irinotecan (CPT-11).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics of irinotecan metabolism and transport: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics of antihypertensive drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Clinical pharmacokinetics of atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

The role of metabolic activation in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Genetical and geographic studies on isoniazid inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Do preclinical testing strategies help predict human hepatotoxic potentials?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Studies on the metabolism of perhexiline in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Perhexiline maleate-associated hepatic injury prevalence and characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Metabolic therapeutics in angina pectoris: history revisited with perhexiline

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Polymorphic hydroxylation of perhexiline in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Applications of AmpliChip CYP450.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Risk stratification in the long-QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

The significance of QT interval in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Drug-induced torsades de pointes: the evolving role of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenomics and acquired long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Changes in prescribed drug doses after market introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Why aren't lower, effective, OTC doses available earlier by prescription?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Genetic polymorphisms of CYP2C8 in Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Interactions between herbal and conventional medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Herb-drug interactions: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Food-drug interactions via human cytochrome P450 3A (CYP3A).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

21 January 2018

Food-drug interactions

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Concomitant use of antipsychotics and drugs that may prolong the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmaco-metabonomic phenotyping and personalized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

Pharmacogenetics in clinical practice: considerations for testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.889

21 January 2018

Identifiers

DOI

10.2217/14622416.7.6.889

1 reference

15 August 2017

1 reference